Real-world data: principles of use in decision making and in health technology assessment

The use of real-world data (RWD) and real-world evidence (RWE) in process of improving public health, their assessment, and use in decision making is a promising area. Discussions are actively underway about the possibility of using RWD and RWE in routine medical practice of doctors and health care organizers, the weaknesses of these matters and ways to overcome them. Taking into account the considerable amount of information, complexity, and inconsistency of issues under consideration, the article presents the basic principles of using RWD and RWE in decision making, classification of health technologies values, classification of RWE sources, position of RWD studies in the hierarchy of clinical study designs, as well as the ways of their use in complex drug assessment.

1. Mukhortova P.A., Gorkavenko P.V., Strunina Yu.V., Omelyanovskiy V.V., Kalinichenko V.V. Use of real-world data for decision making in Canada and United Kingdom. Real-World Data & Evidence. 2022: 2 (3): 7–19 (in Russ.). https://doi.org/10.37489/2782-3784-myrwd-18.

2. Lin L.W., Ahn J., Bayani D.B.S., et al. Use of real-world data and real-world evidence to support drug reimbursement decision-making in Asia. Available at: https://hiper.nus.edu.sg/wp-content/uploads/2021/05/REALISE-Abridged-guidance-for-users-of-HTA_20201104-version-1.0-2.pdf (in Russ.) (accessed 03.03.2023).

3. Borzova M.A. Real-world data: general regulatory approaches in the EU and Japan. Real-World Data & Evidence. 2022: 2 (1): 11–6 (in Russ.). https://doi.org/10.37489/2782-3784-myrwd-7.

4. NICE real-world evidence framework. Available at: https://www.nice.org.uk/corporate/ecd9/resources/nice-realworld-evidence-framework-pdf-1124020816837 (in Russ.) (accessed 03.03.2023).

5. Framework for FDA’s real-world evidence program. Available at: https://www.fda.gov/media/120060/download (in Russ.) (accessed 03.03.2023).

6. Canada’s Drug and Health Technology Agency. Guidance for reporting real-world evidence. Available at: https://www.cadth.ca/guidance-reporting-real-world-evidence (in Russ.) (accessed 03.03.2023).

7. Bakker E., Plueschke K., Jonker C.J., et al. Contribution of real-world evidence in European Medicines Agency’s regulatory decision making. Clin Pharmacol Ther. 2022; 113 (1): 135–51. https://doi.org/10.1002/cpt.2766.

8. Purpura C.A., Garry E.M., Honig N., et al. The role of real-world evidence in FDA-approved new drug and biologics license applications. Clin Pharmacol Ther. 2022: 111 (1): 135–44. https://doi.org/10.1002/cpt.2474.

9. Bullement A., Podkonjak T., Robinson M.J., et al. Real-world evidence use in assessments of cancer drugs by NICE. Int J Technol Assess Health Care. 2020: 36 (4): 388–94. https://doi.org/10.1017/S0266462320000434.

10. Lau C., Dranitsaris G. Impact of regulatory approval status on CADTH reimbursement of oncology drugs and role of real-world evidence on conditional approvals from 2019 to 2021. Curr Oncol. 2022: 29 (11): 8031–42. https://doi.org/10.3390/curroncol29110635.

11. Kolbin A.S. Resolution based on the results of the conference: "RWD/ RWE – research tools of real-world clinical practice today and tomorrow". Real-World Data & Evidence. 2021; 1 (1): 21–4 (in Russ.). https://doi.org/10.37489/2782-3784-myrwd-5.

12. Kolbin A.S. Resolution based on the results of the III annual scientific and practical conference “Real clinical practice in a changing world. Challenges and solutions”. Real-World Data & Evidence. 2022: 2 (3): 35–41 (in Russ.). https://doi.org/10.37489/2782-3784-myrwd-20.

13. Novoderezhkina E.A., Zyryanov S.К. The role of real world data and real world evidence in health technology assessment. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022: 15 (3): 380–9 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.120.

14. Kurylev A.A., Zhuravkov A.A., Kolbin A.S. Real-world clinical practice in health technology assessment: state of the art for 2022. RealWorld Data & Evidence. 2022: 2 (4): 1–9 (in Russ.). https://doi.org/10.37489/2782-3784-myrwd-21.

15. Decision of the Council of the Eurasian Economic Commission of 03.11.2016 No. 78 (ed. 23.09.2022) “On the Rules for registration and examination of medicines for medical use”. Available at: https://docs.cntd.ru/document/456026097 (in Russ.) (accessed 12.01.2023).

16. Kolbin A.S. (Ed.) Real clinical practice research. Moscow: OKI: Buki Vedi; 2020: 208 pp. (in Russ.).

17. Goldina T.A., Kolbin A.S., Belousov D.Yu., Borovskaya V.G. Review of real-world data study. Kachestvennaya Klinicheskaya Praktika / Good Clinical Practice. 2021; 1: 56–63 (in Russ.). https://doi.org/10.37489/2588-0519-2021-1-56-63.

18. Last J.М. (Ed.) A dictionary of epidemiology. 4th ed. Oxford University Press; 2001: 196 pp.

19. Goldina T.A., Suvorov N.I. Real-world data studies: from data to health technology assessment and decision-making in healthcare. Medical Technologies. Assessment and Choice. 2018; 1: 21–9 (in Russ.).

20. Decree of the Government of the RF of 28.08.2014 No. 871 (ed. 03.12.2020) “On approval of the Rules for the formation of lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care”. Available at: https://base.garant.ru/70728348/ (in Russ.) (accessed 12.01.2023).

21. Omelyanovskiy V.V., Avxentyeva M.V., Sura M.V., et al. Methodological recommendations for the evaluation of drug comparative clinical efficacy and safety. Мoscow: Center for Healthcare Quality Assessment and Control; 2016: 58 pp. (in Russ.).